Hydroxyethyl starch or saline for fluid resuscitation in intensive care.

Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA, CHEST Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Myburgh J, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Liu B, Lipman J, McArthur C, McGuinness S, Rajbhandari D, Taylor C, Webb S, Myburgh J, Bellomo R, Cass A, Correa M, Finfer S, Gattas D, Glass P, Harland J, Lee J, Liu B, Lipman J, McArthur C, McGuinness S, Ng M, Rajbhandari D, Taylor C, Webb S, Young D, Cook D, Roberts I, Brown J, Gilder E, McGuinness S, Parke R, Bellomo R, Eastwood G, Peck L, Warrillow S, Young H, Boschert C, Broadfield E, Edington J, Fletcher J, Koch G, Porwal S, Smith J, Nand K, Poojara L, Reece G, Sara T, Ellem K, Vale S, Chan S, Fulton E, Leditschke A, Mitchell I, Sowiak K, Russell-Brown J, Rodgers H, Taylor E, van Haren F, Whyte R, Bowie D, Gibson A, Henderson S, Hitchings L, Knight D, Mehrtens J, Noble S, Sugden D, Shaw G, Cheung W, Lawrence P, Milliss D, Thanakrishnan G, Wong H, Ihle B, Padayachee L, Pather V, Robertson M, Allsop S, Botha J, Haji K, Jones K, Blythe D, Butler V, De Keulenaer B, Palermo A, Bone A, Cattigan C, Elderkin T, Fraser M, Orford N, Salerno T, Hardie M, Harrigan P, Aneman A, Aziz A, Micallef S, Parker S, Parr M, Parrish T, Tam V, Varghese B, Morgan J, Presneill J, Sutton J, Bond R, Cole L, Cuzner C, Gresham R, Nikas M, Palejs P, Seppelt I, Weisbrodt L, Whereat S, Bell J, Flanagan A, Holland U, Lawrey Y, Liang J, Duke G, Green J, Park M, Reade M, Sungkar J, Bass F, Bihari D, Edhouse P, Sana M, Shehabi Y, Walker A, Boots R, Deans R, Dunlop R, Jarrett P, Lassig-Smith M, Lipman J, Starr T, Stuart J, Wang L, Beswick A, Cooper D, McAllister R, Rigg D, Turner A, Bass F, Bird S, Bradford C, Delaney A, Finfer S, Foote C, Harris R, Hammond N, Lee R, Macken L, McEvoy G, O'Connor A, Potter J, Raper R, Steel E, Yarad E, Buhr H, Cowell J, Daley M, Gattas D, Gowda S, Herkes R, Hislop R, Honeysett L, Koelzow H, Lucey M, O'Leary M, Phipps P, Rajbhandari D, Rees C, Totaro R, Woolfe C, Inskip D, Miller J, Myburgh J, Saxena M, Sidoli R, Holmes J, Santamaria J, Smith R, Tobin A, Browne T, Bryers D, Goodson J, Houghton J, Nelson S, Durning J, Forrest A, La Pine M, McCracken G, Terlesk H, van Haren F, Andrews L, Barry B, Dinsdale R, Golds H, Hicks P, Mackle D, Ongley J, Phillips T, Poynter C, Psirides A, Sturland S, Ure R, Williams B, Young P, Partanen A, Pascoe R, Rosser B, Stanton A, Trehane A, Venkatesh B, Bates S, Butler J, Keen L, McGain F, Tippett A, Banerjee A, Clark P, Kong J, Morrison M, Nayyar V, Skelly C, Stachowski E, Bellomo R, Cass A, Dan A, Finfer S, Gattas D, Glass P, Hammond N, Jan S, Liu B, MacMahon S, Myburgh J, Norton R, Perkovic V, Taylor C, Correa M, Goldsmith D, Gould A, Hannah D, Harward M, Ham L, Harland J, Lee J, Myburgh A, Ng M, Rajbhandari D, Ryan S, Thompson K, Vijayan B, Willenberg L, Billot L, Bompoint S, Heritier S, Li Q, Mysore J, Bidencope R, Cole J, Fisher R, Kramer D, Regan T, Baron JF, Bepperling F, Gottwald T, Holler M, Jungheinrich C, Kulkarni H, Maltas M, Ott B, Westphal M, Godfrey G, Marando D, Miles S, Minton A, Simpson J

Abstract

The safety and efficacy of hydroxyethyl starch (HES) for fluid resuscitation have not been fully evaluated, and adverse effects of HES on survival and renal function have been reported.We randomly assigned 7000 patients who had been admitted to an intensive care unit (ICU) in a 1:1 ratio to receive either 6% HES with a molecular weight of 130 kD and a molar substitution ratio of 0.4 (130/0.4, Voluven) in 0.9% sodium chloride or 0.9% sodium chloride (saline) for all fluid resuscitation until ICU discharge, death, or 90 days after randomization. The primary outcome was death within 90 days. Secondary outcomes included acute kidney injury and failure and treatment with renal-replacement therapy.A total of 597 of 3315 patients (18.0%) in the HES group and 566 of 3336 (17.0%) in the saline group died (relative risk in the HES group, 1.06; 95% confidence interval [CI], 0.96 to 1.18; P=0.26). There was no significant difference in mortality in six predefined subgroups. Renal-replacement therapy was used in 235 of 3352 patients (7.0%) in the HES group and 196 of 3375 (5.8%) in the saline group (relative risk, 1.21; 95% CI, 1.00 to 1.45; P=0.04). In the HES and saline groups, renal injury occurred in 34.6% and 38.0% of patients, respectively (P=0.005), and renal failure occurred in 10.4% and 9.2% of patients, respectively (P=0.12). HES was associated with significantly more adverse events (5.3% vs. 2.8%, P<0.001).In patients in the ICU, there was no significant difference in 90-day mortality between patients resuscitated with 6% HES (130/0.4) or saline. However, more patients who received resuscitation with HES were treated with renal-replacement therapy. (Funded by the National Health and Medical Research Council of Australia and others; CHEST ClinicalTrials.gov number, NCT00935168.).